TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22196897

Group type: EXPERIMENTAL
Intervention: GC Initial ZR
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Vita VM9
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: IPS e.max Ceram
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: IPS e.max Ceram (censored for total fracture)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: IPS e.max Ceram (total fracture with chipping)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: GC Initial ZR (total fracture with chipping)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: VITA VM9 (total fracture with chipping)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: VITA VM9 (Weibull distributed data)
Number of subjects: 90
Study: 19508549

Group type: EXPERIMENTAL
Intervention: Local infiltration of the skin prior to incision with bupivacaine (Group A)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Half the bupivacaine infiltrated into the skin and the other half deep-to-external oblique (Group B)
Number of subjects: 84
Study: 17971585

Group type: EXPERIMENTAL
Intervention: Protracted radiotherapy (P-RT)
Number of subjects: 451

Group type: COMPARATOR
Intervention: Split-course radiotherapy (SC-RT)
Number of subjects: 451
Study: 17061753

Group type: EXPERIMENTAL
Intervention: Community health fairs
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Private practice referrals
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Participant referrals
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Community clinic referrals
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Community advertising and marketing
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Chart review
Number of subjects: 236
Study: 15015273

Group type: EXPERIMENTAL
Intervention: Tianzhi Granule (TZK) 0.5 g/bag, taken one bag three times a day for two courses of one month each
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Tianzhi Granule (TZK)
Number of subjects: 200
Study: 11543498

Group type: EXPERIMENTAL
Intervention: Psychophysiological monitoring during isolation in the HUBES experiment
Number of subjects: 9
Study: 8739664

Group type: EXPERIMENTAL
Intervention: Mirtazapine, 15‐45 mg/day
Number of subjects: 115

Group type: COMPARATOR
Intervention: Amitriptyline, 30‐90 mg/day
Number of subjects: 115
Study: 1884876

Group type: EXPERIMENTAL
Intervention: Bromhexine 72 mg daily for one month
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 6760146

Group type: EXPERIMENTAL
Intervention: Cefaclor
Number of subjects: 214

Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 214
Study: 30652528

Group type: EXPERIMENTAL
Intervention: Paleolithic diet plus supervised exercise training 3 hours per week (PD - EX)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Paleolithic diet and standard-care exercise recommendations (PD)
Number of subjects: 22
Study: 28903733

Group type: EXPERIMENTAL
Intervention: Interactive web-based curriculum (6 hours) covering communication skills, basics of genetic testing, risk assessment, ELSI issues, and practice behaviors.
Number of subjects: 121

Group type: COMPARATOR
Intervention: Traditional Continuing Medical Education (CME) approach (clinical review articles).
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Interactive web-based curriculum (6 hours).
Number of subjects: 121

Group type: COMPARATOR
Intervention: Both groups (Intervention and Control).
Number of subjects: 121
Study: 24284692

Group type: COMPARATOR
Intervention: No glare
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Direct glare
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Indirect glare
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Desk luminary glare
Number of subjects: 16
Study: 24126295

Group type: EXPERIMENTAL
Intervention: CHANGE study intervention
Number of subjects: 432

Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 432
Study: 22540851

Group type: EXPERIMENTAL
Intervention: Pulse radiofrequency treatment at 42°C for 120 seconds to the dorsal root ganglion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low intensity test stimulation for 120 seconds
Number of subjects: 0
Study: 19424808

Group type: EXPERIMENTAL
Intervention: Multimodal behavioral intervention plus standardized cardiologic care (n = 39)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Standardized cardiologic care alone (n = 38)
Number of subjects: 77
Study: 17304001

Group type: EXPERIMENTAL
Intervention: Basketball-specific balance training program
Number of subjects: 920

Group type: COMPARATOR
Intervention: Standardized warm-up program
Number of subjects: 920
Study: 14970281

Group type: EXPERIMENTAL
Intervention: Vaccination with autologous tumor cells genetically modified with an adenoviral vector (Ad‐GM) to secrete GM‐CSF; Intradermal injections every 2 weeks for a total of three to six vaccinations
Number of subjects: 83
Study: 11226653

Group type: EXPERIMENTAL
Intervention: Deantigenized dermal matrix with immediate thin autograft
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Dermal matrix covered with bank allograft, autografted 1 week later
Number of subjects: 17

Group type: COMPARATOR
Intervention: Thin donor sites used for dermal matrix coverage
Number of subjects: 17

Group type: COMPARATOR
Intervention: Standard split thickness control graft
Number of subjects: 17
Study: 10209702

Group type: EXPERIMENTAL
Intervention: Mizolastine (10 mg once daily)
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg once daily)
Number of subjects: 632

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 632

Group type: COMPARATOR
Intervention: Mizolastine (in PAR trial)
Number of subjects: 632

Group type: COMPARATOR
Intervention: Placebo (in PAR trial)
Number of subjects: 632
Study: 7796237

Group type: EXPERIMENTAL
Intervention: Post-extubation nasal continuous positive airway pressure (N-CPAP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Post-extubation headbox
Number of subjects: 50
Study: 2254723

Group type: EXPERIMENTAL
Intervention: Intensified conventional treatment (ICT, n = 44)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Regular treatment (RT, n = 53)
Number of subjects: 97
Study: 7410896

Group type: EXPERIMENTAL
Intervention: A/New Jersey subvirion vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whole-virus vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bivalent subvirion vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subvirion vaccines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Natural infection with A/USSR (H1N1)
Number of subjects: 0
Study: 31739130

Group type: EXPERIMENTAL
Intervention: FROGS
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: mini-FROGS
Number of subjects: 228

Group type: COMPARATOR
Intervention: FROGS and mini-FROGS
Number of subjects: 228
Study: 31138319

Group type: EXPERIMENTAL
Intervention: min(three Kruskal-Wallis [KW] test P values) > 0.30
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: min(analysis of variance [ANOVA] P value) > 0.30
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: min(nine possible t test P values) > 0.30
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: min(Wilcoxon rank-sum [WRS] P values) > 0.30
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: multivariate analysis of variance (MANOVA) P value > 0.30
Number of subjects: 0
Study: 27161196

Group type: EXPERIMENTAL
Intervention: Videoinsight® psychological enhancing method (art video shown before rehabilitation sessions for 15 days post-surgery and three times a week for 4 weeks)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (no video support, same rehabilitation protocol)
Number of subjects: 110
Study: 26493989

Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT)
Number of subjects: 291

Group type: COMPARATOR
Intervention: No IPT (Control)
Number of subjects: 291
Study: 23208460

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (400 mg)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Vaginal misoprostol (400 mg)
Number of subjects: 110
Study: 20609098

Group type: EXPERIMENTAL
Intervention: Thigh muscle cross-sectional area (CSA)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Intramuscular lipid
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Intermuscular adipose tissue (IMAT)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: CSA
Number of subjects: 49
Study: 18206407

Group type: EXPERIMENTAL
Intervention: Platelet-rich gel (PRG) treatment
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (no PRG treatment)
Number of subjects: 23
Study: 16339924

Group type: EXPERIMENTAL
Intervention: GnRH-receptor antagonist (graded doses)
Number of subjects: 25
Study: 12571292

Group type: EXPERIMENTAL
Intervention: Autologous chondrocyte implantation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Osteochondral cylinder transplantation
Number of subjects: 40
Study: 10952702

Group type: EXPERIMENTAL
Intervention: Vitamin D 1000 IU/day with calcium and phosphorus supplemented breast milk
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vitamin D 500 IU/day with calcium and phosphorus supplemented breast milk
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Calcium and phosphorus supplemented breast milk
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Calcium and phosphorus unsupplemented breast milk
Number of subjects: 30

Group type: COMPARATOR
Intervention: Preterm infants
Number of subjects: 30

Group type: COMPARATOR
Intervention: Controls (children aged 2 years)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Controls (children aged 9-11 years)
Number of subjects: 30
Study: 8614377

Group type: EXPERIMENTAL
Intervention: Study solution (25 microgram/ml of both amikacin and vancomycin added to the standard solution)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard solution (normal saline + 100 U/ml of heparin)
Number of subjects: 69
Study: 1475987

Group type: EXPERIMENTAL
Intervention: 40 mg oral dose of famotidine administered at 10:00 p.m.
Number of subjects: 38

Group type: COMPARATOR
Intervention: 40 mg oral dose of famotidine administered at 6 p.m.
Number of subjects: 38
Study: 3900079

Group type: EXPERIMENTAL
Intervention: Ioxaglate 320 mg/ml
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ioxaglate 200 mg/ml
Number of subjects: 100
Study: 30266466

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid/carboxymethylcellulose (HA/CMC) instillation
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control (no HA/CMC instillation)
Number of subjects: 76
Study: 27161505

Group type: EXPERIMENTAL
Intervention: Taiwan Odd‐Even Number Sequencing Test (TOENST)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Conventional WM tests
Number of subjects: 364
Study: 27157059

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS
Number of subjects: 0
Study: 25042993

Group type: EXPERIMENTAL
Intervention: Stochastic resonance whole body vibration (SR-WBV) intervention
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sham group (SG)
Number of subjects: 27
Study: 22698488

Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg daily for 7 days
Number of subjects: 54

Group type: COMPARATOR
Intervention: Clopidogrel 75 mg daily for 7 days
Number of subjects: 54
Study: 19887304

Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD) 40 mg/m² on day 1, continuous infusion ifosfamide (IFO) 1700 mg/m² on days 1-3, mesna, every 28 days for 6-9 cycles
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 98
Study: 17823365

Group type: COMPARATOR
Intervention: Statin/ACEI combination treatment at standard doses (STD, ramipril 2.5/simvastatin 20 mg, or atorvastatin 10 mg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Statin/ACEI combination treatment at high doses (HiDo, ramipril 10 mg, or enalapril 20 mg/simvastatin 80 mg, or atorvastatin 40 mg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: High doses (HiDo) treatment
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard doses (STD) treatment
Number of subjects: 22
Study: 17257158

Group type: EXPERIMENTAL
Intervention: NBM+PRP+GTR
Number of subjects: 30

Group type: COMPARATOR
Intervention: NBM+GTR
Number of subjects: 30
Study: 15629285

Group type: EXPERIMENTAL
Intervention: Vitrectomy alone (group A)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Vitrectomy with scleral buckling (group B)
Number of subjects: 68
Study: 11057354

Group type: EXPERIMENTAL
Intervention: Patanol (olopatadine hydrochloride ophthalmic solution 0.1%) with placebo tablet
Number of subjects: 29

Group type: COMPARATOR
Intervention: Claritin (loratadine 10 mg) with placebo
Number of subjects: 29
Study: 9483177

Group type: EXPERIMENTAL
Intervention: Pentaspan (PES)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Albumin
Number of subjects: 12
Study: 8363164

Group type: EXPERIMENTAL
Intervention: Psyllium, 5.1 g twice a day
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Psyllium
Number of subjects: 118
Study: 3746280

Group type: EXPERIMENTAL
Intervention: Phenylalanine loading
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 31551138

Group type: EXPERIMENTAL
Intervention: Alfentanil-propofol admixture (ADMIX)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Alfentanil-atropine followed by propofol (ATRO)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both protocols
Number of subjects: 40
Study: 29993221

Group type: EXPERIMENTAL
Intervention: Bio-modulator patch
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Post-market follow-up
Number of subjects: 140
Study: 26822397

Group type: EXPERIMENTAL
Intervention: Gastrectomy followed by chemotherapy
Number of subjects: 175

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 175
Study: 23875987

Group type: EXPERIMENTAL
Intervention: WTQ-T advertisements (emotional, personal testimonies)
Number of subjects: 3002

Group type: EXPERIMENTAL
Intervention: WTQ-G advertisements (graphic images)
Number of subjects: 3002

Group type: EXPERIMENTAL
Intervention: WTQ-T + HTQ advertisements (combination)
Number of subjects: 3002

Group type: EXPERIMENTAL
Intervention: HTQ advertisements (how-to-quit)
Number of subjects: 3002

Group type: COMPARATOR
Intervention: No-ad condition (control)
Number of subjects: 3002
Study: 22516909

Group type: EXPERIMENTAL
Intervention: Isocaloric carbohydrate (CHO) supplementation
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Carbohydrate-protein (CHO-Pro) supplementation
Number of subjects: 11
Study: 19711036

Group type: EXPERIMENTAL
Intervention: Percutaneous transfemoral TAVI
Number of subjects: 101
Study: 17261389

Group type: EXPERIMENTAL
Intervention: 30-day death or nonfatal myocardial infarction (MI) for whites
Number of subjects: 7073

Group type: EXPERIMENTAL
Intervention: 30-day death or nonfatal myocardial infarction (MI) for African-Americans
Number of subjects: 7073

Group type: EXPERIMENTAL
Intervention: 30-day death or nonfatal myocardial infarction (MI) for Hispanics
Number of subjects: 7073

Group type: EXPERIMENTAL
Intervention: Adjusted odds ratio for African-American patients compared to white patients for 30-day death or MI
Number of subjects: 7073

Group type: EXPERIMENTAL
Intervention: Use of percutaneous coronary intervention
Number of subjects: 7073

Group type: EXPERIMENTAL
Intervention: Use of coronary artery bypass grafting
Number of subjects: 7073

Group type: EXPERIMENTAL
Intervention: Frequencies of hypertension
Number of subjects: 7073

Group type: EXPERIMENTAL
Intervention: 6-month death or MI
Number of subjects: 7073
Study: 15108107

Group type: EXPERIMENTAL
Intervention: Submucosal epinephrine injection (1/10,000)
Number of subjects: 69

Group type: COMPARATOR
Intervention: No injection (control group)
Number of subjects: 69
Study: 11666122

Group type: EXPERIMENTAL
Intervention: Oral TTFCA (60 mg tablets twice daily) for 4 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 50
Study: 9638718

Group type: EXPERIMENTAL
Intervention: Pall BC1B leucocyte-depleting filter for blood cardioplegia
Number of subjects: 40

Group type: COMPARATOR
Intervention: No filter (control group)
Number of subjects: 40
Study: 8013765

Group type: EXPERIMENTAL
Intervention: Propafenone (900 mg/daily)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Flecainide (300 mg/daily)
Number of subjects: 31
Study: 3057851

Group type: EXPERIMENTAL
Intervention: Diltiazem (260 mg/day)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (52 mg/day)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Diltiazem and Hydrochlorothiazide
Number of subjects: 61

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 61
Study: 31809358

Group type: EXPERIMENTAL
Intervention: 2-way texting (2wT) intervention
Number of subjects: 722

Group type: COMPARATOR
Intervention: Routine in-person visits (control)
Number of subjects: 722
Study: 30634094

Group type: EXPERIMENTAL
Intervention: Single leg squat (painful leg group)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Single leg squat (dominant leg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Single leg squat (non-dominant leg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Running (all groups)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Single leg squat (remaining groups)
Number of subjects: 32
Study: 28865588

Group type: EXPERIMENTAL
Intervention: Regular active toe movement
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no active toe movement)
Number of subjects: 100
Study: 25803665

Group type: EXPERIMENTAL
Intervention: Poor social contacts
Number of subjects: 5972

Group type: EXPERIMENTAL
Intervention: High score of skills on seeking guidance and support, problem solving, seeking alternative rewards
Number of subjects: 5972

Group type: EXPERIMENTAL
Intervention: High score of acceptance or resignation, emotional discharge, logical analysis
Number of subjects: 5972

Group type: EXPERIMENTAL
Intervention: Avoidance coping skills
Number of subjects: 5972

Group type: EXPERIMENTAL
Intervention: Approach coping skills
Number of subjects: 5972

Group type: EXPERIMENTAL
Intervention: Social network
Number of subjects: 5972
Study: 23370314

Group type: EXPERIMENTAL
Intervention: Paclitaxel and carboplatin with conatumumab (3 mg/kg)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Paclitaxel and carboplatin with conatumumab (15 mg/kg)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Paclitaxel and carboplatin with placebo
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Conatumumab treatment among V-allele carriers
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Conatumumab treatment among F-allele homozygotes
Number of subjects: 172
Study: 21080021

Group type: EXPERIMENTAL
Intervention: Radiation synovectomy
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Glucocorticoid injection
Number of subjects: 97
Study: 19548858

Group type: EXPERIMENTAL
Intervention: Tesofensine 0.5 mg
Number of subjects: 0
Study: 17092691

Group type: EXPERIMENTAL
Intervention: Paliperidone ER 6 mg
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Paliperidone ER 9 mg
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Paliperidone ER 12 mg
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Paliperidone ER (all doses)
Number of subjects: 628

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 628
Study: 15523955

Group type: COMPARATOR
Intervention: PRK only
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Smoothing technique after PRK
Number of subjects: 54
Study: 15614647

Group type: EXPERIMENTAL
Intervention: Six-week comprehensive coordinative training program
Number of subjects: 75

Group type: COMPARATOR
Intervention: Age-matched healthy individuals
Number of subjects: 75
Study: 11152164

Group type: EXPERIMENTAL
Intervention: Complementary/alternative medicine (CAM) therapies
Number of subjects: 0
Study: 9186298

Group type: EXPERIMENTAL
Intervention: Oral ingestion of 100 g glucose (OGTT)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 100-g protein meal
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Basal glucagon levels
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Glucagon response during OGTT
Number of subjects: 11
Study: 8247951

Group type: EXPERIMENTAL
Intervention: Ketanserin 60 mg daily for 3 weeks
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ketanserin 120 mg daily for 3 weeks
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ketanserin therapy
Number of subjects: 16
Study: 3530444

Group type: EXPERIMENTAL
Intervention: Doxorubicin (ADR) 75 mg/m2 by iv bolus every 3 weeks
Number of subjects: 101

Group type: COMPARATOR
Intervention: Doxorubicin (ADR) 45 mg/m2 by iv bolus every 3 weeks and Mitomycin (MMC) 10 mg/m2 by iv bolus every 6 weeks
Number of subjects: 101
Study: 31329288

Group type: EXPERIMENTAL
Intervention: Dysfunctional coping strategies (measured by COPE 'avoidance strategies' scale)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Major skin involvement (Cluster 1)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Padua Skin-Related QoL questionnaire (PSRQ)
Number of subjects: 72
Study: 30522508

Group type: EXPERIMENTAL
Intervention: Complaints to the ICUs
Number of subjects: 1029

Group type: COMPARATOR
Intervention: Complaints to the general wards
Number of subjects: 1029
Study: 27328578

Group type: EXPERIMENTAL
Intervention: Driving simulator training (12 modules, with varying completion rates: 2-5 modules (n=8, 19%), 6-11 modules (n=7, 17%), all 12 modules (n=27, 64%))
Number of subjects: 215

Group type: COMPARATOR
Intervention: Control group (no simulator training)
Number of subjects: 215
Study: 24612915

Group type: EXPERIMENTAL
Intervention: 2 ml/kg 30% lipid emulsions
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.9% saline solution
Number of subjects: 60
Study: 21632442

Group type: EXPERIMENTAL
Intervention: Diabetic group
Number of subjects: 49

Group type: COMPARATOR
Intervention: Nondiabetic group
Number of subjects: 49
Study: 20697169

Group type: EXPERIMENTAL
Intervention: Subcutaneous terbutaline (250 μg) followed by oral terbutaline (20 mg/d) as maintenance
Number of subjects: 200

Group type: COMPARATOR
Intervention: Intravenous salbutamol (0.1 mg) followed by oral salbutamol (24 mg/d) as maintenance
Number of subjects: 200
Study: 18490472

Group type: EXPERIMENTAL
Intervention: Anatomic double-bundle reconstruction
Number of subjects: 328

Group type: COMPARATOR
Intervention: Single-bundle reconstruction
Number of subjects: 328

Group type: COMPARATOR
Intervention: Both procedures
Number of subjects: 328